证券代码：839729 证券简称：永顺生物 公告编号：2023-006 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2023 年第一次临时股东大会。 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次股东大会的召开符合《公司法》等法律、规范性文件和《公司章程》的 相关规定，会议召开合法合规。 广东永顺生物制药股份有限公司 关于召开 2023 年第一次临时股东大会通知公告（提供网络投票） （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 同一表决权只能选择现场投票和网络投票方式中的一种。同一表决权出现 重复表决的以第一次投票结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2023 年 2 月 3 日 14：30。 2、网络投票起止时间：2023 年 2 月 2 日 15:00—2023 年 2 月 3 日 15:00。 登记在册的股东可通过中国证券登记结算有限责任公司（以下简称"中国结 ...

一、《关于预计公司2023年度日常性关联交易的议案》的事前认可意见和 独立意见 （一）事前认可意见 公司董事会审议《关于预计公司与广东省现代农业集团有限公司及其关联方 2023年度日常性关联交易的议案》《关于预计公司与广东省农业科学院动物卫生 研究所2023年度日常性关联交易的议案》事项前，公司已将相关材料递交独立董 事审阅，我们认为公司与关联方开展的业务属公司正常经营行为，与关联方交易 的价格按照市场公允价格确定，不存在损害公司和中小股东利益的行为。我们同 意将上述事项提交公司董事会审议，关联董事应履行回避表决程序。 （二）独立意见 经审阅，我们认为公司根据年度经营计划对2023年日常性关联交易往来情况 进行预计，有利于公司日常业务的开展和执行。本次预计事项在审议时关联董事 回避表决，表决程序合法公正，符合相关法律法规和《公司章程》的规定。 同 证券代码：839729 证券简称：永顺生物 公告编号：2023-007 广东永顺生物制药股份有限公司 独立董事关于第四届董事会第十二次会议 相关事项的事前认可意见及独立意见 广东永顺生物制药股份有限公司于2023年1月13日召开第四届董事会第十二 次会议。我们作为公 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-004 广东永顺生物制药股份有限公司 关于预计 2023 年日常性关联交易的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 日常性关联交易预计情况 （一） 预计情况 单位：元 | 关联交易类别 | 主要交易内容 | 预计 2023 年发 | 2022 年与关联 方实际发生金 | 预计金额与上年实际发 | | --- | --- | --- | --- | --- | | | | 生金额 | | 生金额差异较大的原因 | | | | | 额 | | | 购买原材料、 | 接受关联方广东省农 | 1,100,000.00 | 119,165.00 | 业务需要，预计支付关 | | 燃料和动力、 | 业科学院动物卫生研 | | | 联方研发及技术服务费 | | 接受劳务 | 究所研发及技术服务 | | | 用同比增加。 | | | 向关联方销售疫苗 | 6,300,000.00 | 2,297,767.00 | 预计 2023 年关联方 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-002 广东永顺生物制药股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 广东永顺生物制药股份有限公司（以下简称"公司"）分别于 2022 年 3 月 22 日和 2022 年 4 月 13 日召开的第四届董事会第七次会议和 2021 年年度股东大 会，审议通过了《关于拟续聘会计师事务所的议案》，同意续聘天健会计师事务 所（特殊普通合伙）（以下简称"天健"）为公司 2022 年度审计机构。具体内 容详见公司于 2022 年 3 月 23 日在北京证券交易所官方信息披露平台： https://www.bse.cn/）发布的《拟续聘会计师事务所公告》（公告编号：2022-035） 以及 2022 年 4 月 14 日发布的《2021 年年度股东大会决议公告》（公告编号： 2022-043）。 近日，公司收到天健《关于广东永顺生物制药股份有限公司拟变更签字注册 会计师的情况说明》，现将具体情况公告如下： ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-001 广东永顺生物制药股份有限公司 回购进展情况公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 回购方案基本情况 广东永顺生物制药股份有限公司（以下简称"公司"）于 2022 年 8 月 11 日召开公 司第四届董事会第十次会议、第四届监事会第十一次会议，审议通过《关于<广东永顺 生物制药股份有限公司回购股份方案>的议案》，具体内容详见公司于 2022 年 8 月 11 日在北京证券交易所信息披露平台(http://www.bse.cn/)上披露的《回购股份方案公 告》（公告编号：2022-059）。回购方案主要内容如下： 具体回购股份使用资金总额以回购结束实际情况为准。 （一）回购用途及目的 基于对公司未来发展前景的信心和公司价值的认可，为建立完善的长效激励约束机 制，充分调动公司员工的积极性，促进公司持续稳定健康发展，在综合考虑公司经营情 况、财务状况及未来盈利能力等因素的基础上，公司拟以自有资金回购公司股份，用于 公司实施 ...

证券代码：839729 证券简称：永顺生物 公告编号：2022-048 广东永顺生物制药股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 广东永顺生物制药股份有限公司（以下简称"公司"）于 2022 年 5 月 11 日接待了 8 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 5 月 11 日 调研地点：广东永顺生物制药股份有限公司二楼会议室 调研形式：现场调研 调研机构：长城证券股份有限公司、广东丰盛长天投资有限公司、广州永沣 投资控股有限公司、广州和易控股有限公司、吉富创业投资股份有限公司、国盛 证券有限责任公司、佛山泓文投资咨询有限公司、海通期货股份有限公司 上市公司接待人员：副总经理、董事会秘书吴子舟，总经理助理杨傲冰 二、 ...

证券代码：839729 证券简称：永顺生物 公告编号：2022-065 广东永顺生物制药股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 广东永顺生物制药股份有限公司（以下简称"公司"）于 2022 年 9 月 20 日接待了 8 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 9 月 20 日 调研地点：广东永顺生物制药股份有限公司二楼会议室 调研形式：现场调研 调研机构：湘财证券股份有限公司、第一创业证券股份有限公司、中金资本 管理广东有限公司、广发银行股份有限公司、广东弘图广电投资有限公司、中信 银行股份有限公司、交通银行股份有限公司、广州华宸管理咨询有限公司 上市公司接待人员：董事、总经理林德锐先生，副总经理、董事会秘书吴子 舟先生，财务负责人李秋红女士 二、 调研的主要问题及公司回复概要 问题 1：国产宠物疫苗，药品需求大，未来前景可观，贵公司未来的业务是 否会考虑加大宠物相关疫苗的投资研发？ 回复：我国宠物行业规模基 ...

证券代码：839729 证券简称：永顺生物 公告编号：2022-068 广东永顺生物制药股份有限公司 关于接待机构投资者调研情况的公告 | --- | --- | |------------------------------------------------------------------------|-------| | | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | | 带法律责任。 | | 广东永顺生物制药股份有限公司（以下简称"公司"）于 2022 年 9 月 27 日接待了 6 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 9 月 27 日 调研地点：广东永顺生物制药股份有限公司二楼会议室 调研形式：现场调研 调研机构：海通证券股份有限公司、海通期货股份有限公司、广东金羊基金 管理有限公司、广州市罗爵资产管理有限公司、广州中投立赢私募证券投资基金 管理有限公司、招商银行股份有限公司 上市公司接待人员：副总经理、董事会秘书吴子舟先生，财务 ...

Regulatory Approvals and Certifications - In February 2022, the company received production approval for two avian influenza vaccines, with approval numbers 190592368 and 190592369[3]. - The company has received a high-tech enterprise certificate valid for three years, allowing a reduced corporate income tax rate of 15% for the years 2020 to 2022[11]. - The company has obtained two new veterinary drug certificates for aquatic vaccines, but market recognition is lower than expected, leading to no revenue from these products yet[11]. - The company holds 22 authorized patents, including 13 invention patents, and has 18 vaccine products under research and development[10]. - The company has developed a new cell culture production technology for animal vaccines, which has received national patent authorization[31]. Financial Performance - The company's operating revenue for the current period is CNY 155,508,444.83, a decrease of 17.35% compared to CNY 188,160,457.30 in the same period last year[25]. - The net profit attributable to shareholders of the listed company is CNY 35,315,527.79, down 39.00% from CNY 57,890,814.02 in the previous year[25]. - The gross profit margin has decreased to 64.67% from 71.27% year-on-year[25]. - The basic earnings per share have dropped to 0.13 from 0.21, reflecting a decline of 38.10%[25]. - Non-recurring gains and losses impacted the net profit by RMB 6,999,400, representing 19.82% of the net profit for the period[10]. Revenue Sources and Distribution - The revenue from the distribution model accounted for 28.33% of the total operating income during the reporting period[10]. - Vaccine sales revenue was 150.60 million yuan, down 20.04 million yuan, or 11.74% year-on-year, mainly due to delays in government procurement caused by changes in avian influenza strains[41]. - Revenue from technology transfer was CNY 4,906,809.03, a significant drop of 71.90% year-on-year[60]. - The revenue from inactivated poultry vaccines fell by 24.72% to CNY 49,005,225.05, with a gross margin of 31.06%[57]. Operational Challenges and Risks - The company faces risks related to fluctuations in the livestock and poultry farming industry, which could affect vaccine demand and overall performance[9]. - The company faces risks related to the inability to recover accounts receivable on time, which could adversely affect operational performance[11]. - Environmental protection measures have increased operational costs, and failure to comply with national standards could harm the company's reputation and operations[11]. - The company is focusing on enhancing product quality and technical improvements, including the acquisition of an energy online monitoring system to reduce costs and improve efficiency[42]. Shareholder and Governance Information - The company has a total of 273,350,000 shares, with 80,244,567 shares (29.36%) being unrestricted and 193,105,433 shares (70.64%) being restricted[111]. - Major shareholders have signed commitments to avoid competition and reduce related party transactions, with these commitments being fulfilled during the reporting period[101][102]. - The company has no controlling shareholder or actual controller, ensuring independence in governance[133]. - The management team has committed to improving corporate governance structures, which is currently in progress[93]. Cash Flow and Investment - Operating cash flow decreased by 38.80% to ¥20,595,869.57, reflecting reduced operational efficiency[27]. - The company reported a net cash flow from operating activities of CNY 20,595,869.57, a decline of 38.80% from the previous year[63]. - The company has utilized CNY 8,785,773.95 of the raised funds for working capital, which is 99.99% of the planned amount[127]. - The total amount of raised funds that have been changed in purpose is CNY 0, indicating compliance with regulatory requirements[126]. Research and Development - The company invested 12.13 million yuan in R&D, accounting for 7.80% of operating revenue, and obtained 1 utility model patent and 2 clinical trial approvals for veterinary biological products[42]. - The company is focusing on enhancing its R&D management and collaboration with research institutions to reduce the uncertainty in new product development[78]. Market Position and Strategy - The company is designated as a key producer of high pathogenic avian influenza vaccines, with sales primarily through government procurement[9]. - The company plans to enhance its product line and sales channels to mitigate risks associated with fluctuations in the livestock breeding industry[71]. - The company aims to improve its market share by increasing development efforts with distributors and large-scale breeding customers[73]. Compliance and Legal Matters - There are no significant lawsuits or arbitration matters reported during the period, with a total claim amount of 4.98 million yuan, representing 0.75% of net assets[87]. - The company has no reported instances of shareholders or related parties occupying or transferring company funds or assets[88]. - The company has made provisions for bad debts according to established accounting policies, but risks remain if major clients face financial difficulties[82].

Financial Performance - Net profit attributable to shareholders for Q1 2022 was CNY 17,329,287.65, a decrease of 46.62% compared to CNY 32,464,384.86 in Q1 2021[18] - Operating revenue for Q1 2022 was CNY 78,677,625.48, down 25.46% from CNY 105,555,621.75 in the same period last year[18] - The company's cash flow from operating activities for Q1 2022 was CNY 156,921.63, a significant decline of 98.54% compared to CNY 10,747,970.03 in Q1 2021[18] - Operating revenue decreased by 25.46% year-on-year, resulting in an operating profit of 19,840,341.00, down 45.55%[22] - Net profit fell to 17,329,287.65, a decline of 46.62% compared to the previous year[22] - Net cash flow from operating activities dropped by 98.54%, amounting to 156,921.63, primarily due to a decrease in sales revenue[23] - The company reported a financial income of CNY 1,195,712.31 in Q1 2022, down from CNY 3,182,549.43 in Q1 2021, a decline of 62.5%[63] - The net profit for the first quarter of 2022 was CNY 17,322,251, a decrease of 46.5% compared to CNY 32,463,364 in the same period of 2021[68] - The operating profit for the first quarter of 2022 was CNY 19,833,124, down 45.5% from CNY 36,433,363 in the first quarter of 2021[68] - The total comprehensive income for the first quarter of 2022 was CNY 17,322,251, a decrease of 46.5% from CNY 32,463,365 in the first quarter of 2021[68] Assets and Liabilities - Total assets as of March 31, 2022, amounted to CNY 816,909,425.89, reflecting a 0.96% increase from CNY 809,181,608.59 at the end of the previous year[18] - The company's total liabilities to assets ratio was 11.53% as of March 31, 2022, down from 12.83% at the end of the previous year[18] - The total liabilities decreased to CNY 94,196,583.67 from CNY 103,796,628.70 during the same period[56] - The company's total equity increased to CNY 722,712,842.22 as of March 31, 2022, compared to CNY 705,384,979.89 at the end of 2021[56] - The total current assets as of March 31, 2022, amounted to CNY 558,995,324.61, an increase from CNY 547,385,566.32 as of December 31, 2021[54] - The company's fixed assets as of March 31, 2022, were valued at CNY 224,186,004.07, a slight decrease from CNY 230,352,331.89 at the end of 2021[55] Cash Flow - Net cash flow from investing activities was -7,969,673.22, a decrease of 121.24%, mainly due to the redemption of bank wealth management products in the previous year[23] - The investment activities generated a net cash flow of CNY -7,969,673 in the first quarter of 2022, compared to CNY 37,513,662 in the same period of 2021[71] - Cash inflow from operating activities totaled ¥61,793,189.43, a decrease of 32% from ¥90,754,811.00[74] - Cash outflow from operating activities amounted to ¥61,643,415.40, down 23% from ¥80,007,890.35[74] - Net cash flow from operating activities was ¥149,774.03, significantly lower than ¥10,746,920.65 in the previous period[74] - The ending balance of cash and cash equivalents was ¥199,917,514.25, a decrease from ¥440,010,362.03[74] Shareholder Information - The total share capital remains at 273,350,000, with 39.06% held by Guangdong Province and 19.71% by Guangdong Agricultural Science and Technology Investment Co., Ltd.[29] - The company has a total of 4,149 common shareholders[29] - The proportion of unrestricted shares is 29.36%, while restricted shares account for 70.64% of the total[29] - The total shareholding of major shareholders is 221,549,857 shares, representing 81.05% of the total shares[34] Commitments and Compliance - The company has committed to strictly adhering to all promises made during the public offering process, with no violations reported during the period[50] - The company has committed to fulfilling the dilution compensation measures, which have been adhered to without violation during the reporting period[48] - The company assures that the undistributed profits prior to the public offering will be shared among new and old shareholders according to their shareholding ratios, and this commitment has been maintained without breach[49] - The company has commitments in place to avoid related party transactions, which have been fulfilled without any violations during the reporting period[40] - The major shareholders have made commitments to avoid competition and have complied with these commitments during the reporting period[43] Challenges and Future Outlook - The company is facing challenges due to the downturn in the aquaculture industry and the impact of the COVID-19 pandemic[22] - Future strategies and product developments were not detailed in the provided content[22] Legal and Internal Control - There were no significant legal disputes or financial guarantees reported during the period[35] - The company’s internal control systems have been continuously improved, with no significant failures reported[42]